Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01068912 · ClinicalTrials.gov registry record · Phase 2
Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza
A Phase 2 study of Influenza, sponsored by MDVI.
- Completed
- Registry status
- Phase 2
- Development phase
- 530
- Enrollment target
- 20
- Study locations
NCT01068912: Completed Phase 2 study of Influenza, sponsored by MDVI.
NCT01068912 is a Phase 2 study of Influenza that has completed, run by MDVI. The registered enrollment target is 530 participants, below the 36,801-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01068912, a Phase 2 study of Influenza, has completed, sponsored by MDVI.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 530 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, randomized, double-blind, placebo-controlled multicenter study evaluating the efficacy and safety of two doses of favipiravir in adult patients with uncomplicated influenza.
Primary Outcome
Overall time required from first study drug administration to alleviation of the 6 primary influenza symptoms and for temperature (oral) measurements to be less than 38.0°C for patients aged 20 to less than 65 years and less than 37.8°C for patients aged 65 years or older. "Alleviated" was defined as all 6 symptom scores had to be decreased to 1 or below and the decrease remain unchanged for 21.5 hours.
Conditions Studied
Interventions
- DRUG Placebo comparator
- DRUG Favipiravir
Study Locations (20)
Alabama
- #065 - Birmingham
- #156 - Huntsville
- #151 - Mobile
- #155 - Scottsboro
- #173 - Toney
- #161 - Tuscumbia
California
- #059 - Anaheim
- #179 - Anaheim
- #032 - Chino
- #154 - Cypress
- #004 - Garden Grove
- #144 - Long Beach
Arizona
- #089 - Chandler
- #018 - Green Valley
- #110 - Mesa
- #105 - Phoenix
- #188 - Tucson
Arkansas
- #107 - Jonesboro
- #019 - North Little Rock
- #140 - Searcy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
What the finished NCT01068912 record still lists
NCT01068912 is an interventional study that assigns participants to a tested intervention. The registered 530 participants enrollment target is mid-sized for trials with a published cap, below the 36,801-participant average among 156 other Influenza trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Placebo comparator is the first listed.
NCT01068912 names 20 study sites across 4 states, led by Alabama, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT01068912 about?
NCT01068912 is a clinical study titled "Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza". This is a Phase 2, randomized, double-blind, placebo-controlled multicenter study evaluating the efficacy and safety of two doses of favipiravir in adult patients with uncomplicated influenza.
What is the current status of trial NCT01068912?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 530 participants. The study started on 2010-02. Estimated completion is 2012-05.
What conditions does trial NCT01068912 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT01068912?
The interventions under investigation include: Placebo comparator (DRUG), Favipiravir (DRUG).
Who is sponsoring clinical trial NCT01068912?
This trial is sponsored by MDVI, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01068912 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01068912's enrollment target sits among peer trials
530 48th of 156 higher than 109 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
RECRUITING · Phase 2
-
Systems Investigation of Vaccine Responses in Aging and Frailty
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06646276 · 530 participants · Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- NCT06703476 · 530 participants · Phase 3
A Study of Surgical Techniques During Cystectomy
- NCT06880744 · 530 participants · Phase 3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
- NCT07138040 · 530 participants · NA
Re-Engaging AYA Survivors in Cancer-Related Healthcare
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia